20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Over the last two decades, the use of ADHD medication in US youth has markedly increased. However, less is known about ADHD medication use among European children and adolescents. A repeated cross-sectional design was applied to national or regional data extracts from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006-2012. The prevalence of ADHD medication use was assessed, stratified by age and sex. Furthermore, the most commonly prescribed ADHD medications were assessed. ADHD medication use prevalence increased from 1.8% to 3.9% in the Netherlands cohort (relative increase: +111.9%), from 3.3% to 3.7% in the US cohort (+10.7%), from 1.3% to 2.2% in the German cohort (+62.4%), from 0.4% to 1.5% in the Danish cohort (+302.7%), and from 0.3% to 0.5% in the UK cohort (+56.6%). ADHD medication use was highest in 10-14-year olds, peaking in the Netherlands (7.1%) and the US (8.8%). Methylphenidate use predominated in Europe, whereas in the US amphetamines were nearly as common as methylphenidate. Although there was a substantially greater use of ADHD medications in the US cohort, there was a relatively greater increase in ADHD medication use in youth in the four European countries. ADHD medication use patterns in the US differed markedly from those in western European countries.

          Related collections

          Author and article information

          Journal
          Eur Neuropsychopharmacol
          European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
          Elsevier BV
          1873-7862
          0924-977X
          May 2017
          : 27
          : 5
          Affiliations
          [1 ] Faculty of Medicine, Philipps-University Marburg, Marburg, Germany. Electronic address: chrstn.bchmnn@gmail.com.
          [2 ] Department of Primary Care and Population Health, University College London Medical School, London, United Kingdom; Population, Policy and Practice, University College London Institute of Child Health, London, United Kingdom.
          [3 ] Department of Psychiatry, University Medical Center Groningen, University of Groningen, The Netherlands.
          [4 ] Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD, USA.
          [5 ] Department of Health, Long-Term Care and Pensions, SOCIUM Research Center on Inequality and Social Policy, University of Bremen, Germany.
          [6 ] Unit of Pharmacotherapy, -Epidemiology and -Economics, Department of Pharmacy, University of Groningen, The Netherlands.
          [7 ] Department of Health Services Research, Carl von Ossietzky University Oldenburg, Germany.
          [8 ] Life Science Team, Bech-Bruun Law Firm, Copenhagen, Denmark.
          [9 ] Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD, USA; Department of Psychiatry, University of Maryland, Baltimore, MD, USA.
          Article
          S0924-977X(17)30184-0
          10.1016/j.euroneuro.2017.03.002
          28336088
          428fb9a3-d87b-470d-b875-89cc8354cd0a
          History

          Adolescent,Attention Deficit Disorder with Hyperactivity,Child,Methylphenidate,Pharmacoepidemiology

          Comments

          Comment on this article